Traws Pharma, Inc. TRAW
Set alert
0.30 USD -0.01 -1.66%
At close · Oct 30
0.30 0.00 +1.18%
After hours · Oct 30, 4:00 PM ET
0.2876 Day range 0.3098
0.296 52-week range 2.82
- YTD
- -73.81%
- 1 year
- -88.79%
- Open
- 0.3098
- Prev close
- 0.301
- Mkt cap
- 4.55M
- Vol
- 199.52K
- Avg vol
- 582.99K
- EPS
- -1.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2876
- High
- 0.3098
- Forward P/E
- -0.47
- Beta
- 1.41
- Short ratio
- 0.62
- Inst. own
- 21.40%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.96
- 200-d avg
- 11.13
- 1y target
- 6.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -8.81; estimate -6.25; surprise -40.96%
Signals (101)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 29, 2026 | 2 days ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 16, 2026 | 1 month ago |
| RSI: Oversold | Jul 22, 2026 | 3 months ago |
| RSI: Oversold | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| RSI: Oversold | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| SMA: Bullish | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| RSI: Overbought | May 8, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 27, 2026 | 7 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Feb 19, 2026 | 8 months ago |
| SMA: Bearish | Feb 19, 2026 | 8 months ago |
| SMA: Bullish | Feb 10, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 3, 2026 | 9 months ago |
| RSI: Overbought | Jan 26, 2026 | 9 months ago |
| RSI: Overbought | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| RSI: Oversold | Dec 26, 2025 | 10 months ago |
| RSI: Oversold | Dec 18, 2025 | 10 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Dec 11, 2025 | 10 months ago |
| SMA: Bullish | Dec 9, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 9, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 2, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 29, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 24, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 22, 2025 | 1 year ago |
| RSI: Overbought | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 14, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Oct 9, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 3, 2025 | 1 year ago |
| RSI: Overbought | Oct 3, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 24, 2025 | 1 year ago |
| RSI: Overbought | Sep 18, 2025 | 1 year ago |
| RSI: Overbought | Sep 12, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| SMA: Bullish | Sep 3, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 3, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 18, 2025 | 1 year ago |
| SMA: Bearish | Aug 15, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 12, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 24, 2025 | 1 year ago |
| SMA: Bullish | Jun 6, 2025 | 1 year ago |
| SMA: Bearish | Jun 5, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| RSI: Oversold | May 13, 2025 | 1 year ago |
| RSI: Oversold | May 9, 2025 | 1 year ago |
| RSI: Oversold | Apr 28, 2025 | 1 year ago |
| RSI: Oversold | Apr 22, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| RSI: Oversold | Mar 12, 2025 | 1 year ago |
| RSI: Oversold | Feb 24, 2025 | 1 year ago |
| SMA: Bearish | Feb 11, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
| SMA: Bearish | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 8, 2025 | 1 year ago |
| RSI: Overbought | Dec 23, 2024 | 1 year ago |
Key statistics
- Market cap
- 38.03M
- Enterprise value
- 99.78M
- Trailing P/E
- 0.00
- Forward P/E
- -0.47
- PEG ratio
- 0.00
- Price / sales
- 168.28
- Price / book
- 0.99
- EPS (TTM)
- -135.78
- Beta
- 1.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 226.00K
- Revenue growth
- 0.00%
- Free cash flow
- -11.32M
- Total cash
- 16.89M
- Total debt
- 0
- Return on equity
- -1096.52%
- Shares outstanding
- 3.03M
- Short % of float
- 0.43%
- 50-day average
- 4.96
- 200-day average
- 11.13
Analyst view
Consensus: none
Price target (mean) 6.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
TRAW Revenue — quarterly 0
TRAW Net income — quarterly -2.61M
TRAW EPS — quarterly -0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -6.25 | -8.81 | -2.56 | -40.96% |
| Aug 15, 2024 | Jun 1, 2024 | 0.00 | -121.75 | — | — |
| May 15, 2024 | Mar 1, 2024 | -6.00 | -6.00 | 0.00 | 0.00% |
About Traws Pharma, Inc.
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- trawspharma.com
News
- Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock
- Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- HC Wainwright & Co. Reiterates Neutral on Traws Pharma, Maintains $1 Price Target
- Traws Pharma Q2 EPS $(0.16) Beats $(0.34) Estimate
- Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
- Traws Pharma (NASDAQ:TRAW) Shares Up 4.8% – Here’s What Happened
Your note
Sign in to keep a note on TRAW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 20.01% | 605,531 | 7.61M | Sep 29, 2024 |
| Vanguard Group Inc | 0.88% | 26,722 | 335.89K | Sep 29, 2024 |
| Blackrock Inc. | 0.33% | 9,956 | 125.15K | Sep 29, 2024 |
| Bank of America Corporation | 0.07% | 2,138 | 26.87K | Sep 29, 2024 |
| Morgan Stanley | 0.02% | 729 | 9.16K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 630 | 7.92K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.45% | 13,750 | 172.84K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.43% | 12,879 | 161.89K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 5,597 | 70.35K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 1,267 | 15.93K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 926 | 11.64K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 512 | 6.43K | Oct 30, 2024 |